|
1
|
Flores A and Marrero JA: Emerging trends
in hepatocellular carcinoma: focus on diagnosis and therapeutics.
Clin Med Insights Oncol. 8:71–76. 2014.PubMed/NCBI
|
|
2
|
Shinoda M, Kishida N, Itano O, Ei S, Ueno
A, Kitago M, Abe Y, Hibi T, Yagi H, Masugi Y, et al: Long-term
complete response of advanced hepatocellular carcinoma treated with
multidisciplinary therapy including reduced dose of sorafenib: Case
report and review of the literature. World J Surg Oncol.
13:1442015. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Gassmann P, Haier J, Schlüter K,
Domikowsky B, Wendel C, Wiesner U, Kubitza R, Engers R, Schneider
SW, Homey B, et al: CXCR4 regulates the early extravasation of
metastatic tumor cells in vivo. Neoplasia. 11:651–661. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Hattermann K, Holzenburg E, Hans F, Lucius
R, Held-Feindt J and Mentlein R: Effects of the chemokine CXCL12
and combined internalization of its receptors CXCR4 and CXCR7 in
human MCF-7 breast cancer cells. Cell Tissue Res. 357:253–266.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Zhou SL, Dai Z, Zhou ZJ, Wang XY, Yang GH,
Wang Z, Huang XW, Fan J and Zhou J: Overexpression of CXCL5
mediates neutrophil infiltration and indicates poor prognosis for
hepatocellular carcinoma. Hepatology. 56:2242–2254. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Wendt MK, Johanesen PA, Kang-Decker N,
Binion DG, Shah V and Dwinell MB: Silencing of epithelial CXCL12
expression by DNA hypermethylation promotes colonic carcinoma
metastasis. Oncogene. 25:4986–4997. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Schimanski CC, Bahre R, Gockel I, Müller
A, Frerichs K, Hörner V, Teufel A, Simiantonaki N, Biesterfeld S,
Wehler T, et al: Dissemination of hepatocellular carcinoma is
mediated via chemokine receptor CXCR4. Br J Cancer. 95:210–217.
2006. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Chen RX, Song HY, Dong YY, Hu C, Zheng QD,
Xue TC, Liu XH, Zhang Y, Chen J, Ren ZG, et al: Dynamic expression
patterns of differential proteins during early invasion of
hepatocellular carcinoma. PLoS One. 9:e885432014. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Xiang ZL, Zeng ZC, Tang ZY, Fan J, Zhuang
PY, Liang Y, Tan YS and He J: Chemokine receptor CXCR4 expression
in hepatocellular carcinoma patients increases the risk of bone
metastases and poor survival. BMC Cancer. 9:1762009. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Ehtesham M, Winston JA, Kabos P and
Thompson RC: CXCR4 expression mediates glioma cell invasiveness.
Oncogene. 25:2801–2806. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Andre F, Xia W, Conforti R, Wei Y, Boulet
T, Tomasic G, Spielmann M, Zoubir M, Berrada N, Arriagada R, et al:
CXCR4 expression in early breast cancer and risk of distant
recurrence. Oncologist. 14:1182–1188. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Blot E, Laberge-Le Couteulx S, Jamali H,
Cornic M, Guillemet C, Duval C, Hellot MF, Pille JY, Picquenot JM
and Veyret C: CXCR4 membrane expression in node-negative breast
cancer. Breast J. 14:268–274. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Hsu PD, Lander ES and Zhang F: Development
and applications of CRISPR-Cas9 for genome engineering. Cell.
157:1262–1278. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Gori JL, Hsu PD, Maeder ML, Shen S,
Welstead GG and Bumcrot D: Delivery and specificity of CRISPR-Cas9
genome editing technologies for human gene therapy. Hum Gene Ther.
26:443–451. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Katoh M: Epithelial-mesenchymal transition
in gastric cancer (Review). Int J Oncol. 27:1677–1683.
2005.PubMed/NCBI
|
|
16
|
Rhim AD, Mirek ET, Aiello NM, Maitra A,
Bailey JM, McAllister F, Reichert M, Beatty GL, Rustgi AK,
Vonderheide RH, et al: EMT and dissemination precede pancreatic
tumor formation. Cell. 148:349–361. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Creighton CJ, Chang JC and Rosen JM:
Epithelial-mesenchymal transition (EMT) in tumor-initiating cells
and its clinical implications in breast cancer. J Mammary Gland
Biol Neoplasia. 15:253–260. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Huber MA, Kraut N and Beug H: Molecular
requirements for epithelial-mesenchymal transition during tumor
progression. Curr Opin Cell Biol. 17:548–558. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Dasari S and Tchounwou PB: Cisplatin in
cancer therapy: molecular mechanisms of action. Eur J Pharmacol.
740:364–378. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Nakayama K, Kanzaki A, Ogawa K, Miyazaki
K, Neamati N and Takebayashi Y: Copper-transporting P-type
adenosine triphosphatase (ATP7B) as a cisplatin based
chemoresistance marker in ovarian carcinoma: Comparative analysis
with expression of MDR1, MRP1, MRP2, LRP and BCRP. Int J Cancer.
101:488–495. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Su F, Ouyang N, Zhu P, Ouyang N, Jia W,
Gong C, Ma X, Xu H and Song E: Psychological stress induces
chemoresistance in breast cancer by upregulating mdr1. Biochem
Biophys Res Commun. 329:888–897. 2005. View Article : Google Scholar : PubMed/NCBI
|
